tiprankstipranks
Shockwave Medical (SWAV)
NASDAQ:SWAV

Shockwave Medical (SWAV) Stock Price & Analysis

697 Followers

SWAV Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$157.00 - $334.90
Previous Close$334.75
Volume4.71M
Average Volume (3M)1.29M
Market Cap
$12.57B
Enterprise Value$12.35B
Total Cash (Recent Filing)$990.55M
Total Debt (Recent Filing)$770.61M
Price to Earnings (P/E)78.4
Beta0.89
Aug 05, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.27
Shares Outstanding37,543,542
10 Day Avg. Volume1,440,822
30 Day Avg. Volume1,289,120
Standard Deviation0.16
R-Squared0.08
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)23.44
Price to Sales (P/S)17.21
Price to Cash Flow (P/CF)43.80
P/FCF Ratio47.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.91
Enterprise Value/Gross Profit19.45
Enterprise Value/Ebitda64.76
Forecast
Price Target Upside0.07% Upside
Rating ConsensusHold
Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say
Financial PerformanceShockwave generated adjusted EBITDA of $68.5M, surpassing both CG’s estimate of $61.6M and the Street’s $64.1M.
Mergers And AcquisitionsJohnson & Johnson announced a definitive agreement to acquire Shockwave Medical for $335 per share in cash, a transaction value worth $13.1B.
Stock ValuationPrice Target increased to $335, reflecting the proposed acquisition price by Johnson & Johnson.
Bears Say
Acquisition UncertaintyAnalysts see more downside potential for SWAV shares if a deal does not occur compared to the limited upside if it does.
Stock Rating DowngradeDowngrading SWAV shares from Outperform to Market Perform.
Valuation ConcernsConcerns are raised over applying the ABMD EBITDA multiple to SWAV which may lead to inflated valuation expectations.
---

Financials

Annual

Ownership Overview

11.79%43.45%39.30%5.47%
11.79% Insiders
39.30% Other Institutional Investors
5.47% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

The estimated number of people who visited one or more of the websites owned by Shockwave Medical
Desktop Users
Mobile Users

SWAV FAQ

What was Shockwave Medical’s price range in the past 12 months?
Shockwave Medical lowest stock price was $157.00 and its highest was $334.90 in the past 12 months.
    What is Shockwave Medical’s market cap?
    Currently, no data Available
    When is Shockwave Medical’s upcoming earnings report date?
    Shockwave Medical’s upcoming earnings report date is Aug 05, 2024 which is in 20 days.
      How were Shockwave Medical’s earnings last quarter?
      Shockwave Medical released its earnings results on May 06, 2024. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $0.989 by $0.451.
        Is Shockwave Medical overvalued?
        According to Wall Street analysts Shockwave Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Shockwave Medical pay dividends?
          Shockwave Medical does not currently pay dividends.
          What is Shockwave Medical’s EPS estimate?
          Shockwave Medical’s EPS estimate is $1.18.
            How many shares outstanding does Shockwave Medical have?
            Shockwave Medical has 37,544,000 shares outstanding.
              What happened to Shockwave Medical’s price movement after its last earnings report?
              Shockwave Medical reported an EPS of $1.44 in its last earnings report, beating expectations of $0.989. Following the earnings report the stock price went up 0.148%.
                Which hedge fund is a major shareholder of Shockwave Medical?
                Among the largest hedge funds holding Shockwave Medical’s share is Gilder Gagnon Howe & Co LLC.. It holds Shockwave Medical’s shares valued at 171M.
                  ---

                  Company Description

                  Shockwave Medical

                  Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.
                  ---

                  SWAV Earnings Call

                  Q4 2024
                  0:00 / 0:00
                  ---

                  SWAV Revenue Breakdown

                  72.42%72.42%26.61%0.60%0.37%
                  72.42% Coronary
                  26.61% Peripheral
                  0.60% Reducer
                  0.37% Other
                  tipranks
                  ---

                  SWAV Stock 12 Month Forecast

                  Average Price Target

                  $335.00
                  ▲(0.07% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"181":"$181","336":"$336","219.75":"$219.8","258.5":"$258.5","297.25":"$297.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":335,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$335.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":335,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$335.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":335,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$335.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[181,219.75,258.5,297.25,336],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,330.38,330.7353846153846,331.09076923076924,331.44615384615383,331.8015384615385,332.1569230769231,332.5123076923077,332.8676923076923,333.2230769230769,333.5784615384615,333.93384615384616,334.28923076923076,334.6446153846154,{"y":335,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,330.38,330.7353846153846,331.09076923076924,331.44615384615383,331.8015384615385,332.1569230769231,332.5123076923077,332.8676923076923,333.2230769230769,333.5784615384615,333.93384615384616,334.28923076923076,334.6446153846154,{"y":335,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,330.38,330.7353846153846,331.09076923076924,331.44615384615383,331.8015384615385,332.1569230769231,332.5123076923077,332.8676923076923,333.2230769230769,333.5784615384615,333.93384615384616,334.28923076923076,334.6446153846154,{"y":335,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":281.66,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":289.15,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":261.77,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.65,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.41,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.2,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":215.69,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.2,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.25,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.53,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.41,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":326.34,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.38,"date":1714694400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Atricure
                  NovoCure
                  Tandem Diabetes Care
                  TransMedics Group

                  Best Analysts Covering SWAV

                  1 Year
                  Travis SteedBank of America Securities
                  1 Year Success Rate
                  8/9 ratings generated profit
                  89%
                  1 Year Average Return
                  +27.96%
                  assigned a buy rating 4 months ago
                  Copying Travis Steed's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +27.96% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis